Early-Life Experience, Epigenetics, and the Developing Brain
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A
The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A. Dawson, Ph.D., Huy Q. Nguyen, B.S., and Ping Li, B.S. Preclinical evidence has suggested a possible role for the 5-HT6 increases in extracellular glutamate levels in both frontal receptor in the treatment of cognitive dysfunction. However, cortex and dorsal hippocampus, respectively. These effects were currently there is little neurochemical evidence suggesting the completely attenuated by infusion of tetrodotoxin but mechanism(s) which may be involved. Using the selective unaffected by the muscarinic antagonist, atropine. Here we 5-HT6 antagonist SB-271046 and in vivo microdialysis, we demonstrate for the first time the selective enhancement of have evaluated the effects of this compound on the modulation excitatory neurotransmission by SB-271046 in those brain of basal neurotransmitter release within multiple brain regions regions implicated in cognitive and memory function, and of the freely moving rat. SB-271046 produced no change in provide mechanistic evidence in support of a possible basal levels of dopamine (DA), norepinephrine (NE) or 5-HT therapeutic role for 5-HT6 receptor antagonists in the in the striatum, frontal cortex, dorsal hippocampus or nucleus treatment of cognitive and memory dysfunction. accumbens. Similarly, this compound had no effect on [Neuropsychopharmacology 25:662–668, 2001] excitatory neurotransmission in the striatum or nucleus © 2001 American College of Neuropsychopharmacology. accumbens. Conversely, SB-271046 produced 3- and 2-fold Published by Elsevier Science Inc. KEY WORDS: 5-HT6 receptor; SB-271046; Microdialysis; sma et al. 1993; Ruat et al. -
Ecological Developmental Biology and Disease States CHAPTER 5 Teratogenesis: Environmental Assaults on Development 167
Integrating Epigenetics, Medicine, and Evolution Scott F. Gilbert David Epel Swarthmore College Hopkins Marine Station, Stanford University Sinauer Associates, Inc. • Publishers Sunderland, Massachusetts U.S.A. © Sinauer Associates, Inc. This material cannot be copied, reproduced, manufactured or disseminated in any form without express written permission from the publisher. Brief Contents PART 1 Environmental Signals and Normal Development CHAPTER 1 The Environment as a Normal Agent in Producing Phenotypes 3 CHAPTER 2 How Agents in the Environment Effect Molecular Changes in Development 37 CHAPTER 3 Developmental Symbiosis: Co-Development as a Strategy for Life 79 CHAPTER 4 Embryonic Defenses: Survival in a Hostile World 119 PART 2 Ecological Developmental Biology and Disease States CHAPTER 5 Teratogenesis: Environmental Assaults on Development 167 CHAPTER 6 Endocrine Disruptors 197 CHAPTER 7 The Epigenetic Origin of Adult Diseases 245 PART 3 Toward a Developmental Evolutionary Synthesis CHAPTER 8 The Modern Synthesis: Natural Selection of Allelic Variation 289 CHAPTER 9 Evolution through Developmental Regulatory Genes 323 CHAPTER 10 Environment, Development, and Evolution: Toward a New Synthesis 369 CODA Philosophical Concerns Raised by Ecological Developmental Biology 403 APPENDIX A Lysenko, Kammerer, and the Truncated Tradition of Ecological Developmental Biology 421 APPENDIX B The Molecular Mechanisms of Epigenetic Change 433 APPENDIX C Writing Development Out of the Modern Synthesis 441 APPENDIX D Epigenetic Inheritance Systems: -
M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Defic
M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats Geoffrey B. Varty, Ph.D., Vaishali P. Bakshi, Ph.D., and Mark A. Geyer, Ph.D. a In a recent study using Wistar rats, the serotonergic 5-HT2 1 receptor agonist cirazoline disrupts PPI. As risperidone a receptor antagonists ketanserin and risperidone reduced the and M100907 have affinity at the 1 receptor, a final study disruptive effects of the noncompetitive N-methyl-D- examined whether M100907 would block the effects of aspartate (NMDA) antagonist dizocilpine on prepulse cirazoline on PPI. Risperidone partially, but inhibition (PPI), suggesting that there is an interaction nonsignificantly, reduced the effects of dizocilpine in Wistar between serotonin and glutamate in the modulation of PPI. rats, although this effect was smaller than previously In contrast, studies using the noncompetitive NMDA reported. Consistent with previous studies, risperidone did antagonist phencyclidine (PCP) in Sprague–Dawley rats not alter the effects of dizocilpine in Sprague–Dawley rats. found no effect with 5-HT2 antagonists. To test the hypothesis Most importantly, M100907 pretreatment fully blocked the that strain differences might explain the discrepancy in effect of dizocilpine in both strains; whereas SDZ SER 082 these findings, risperidone was tested for its ability to had no effect. M100907 had no influence on PPI by itself reduce the PPI-disruptive effects of dizocilpine in Wistar and did not reduce the effects of cirazoline on PPI. These and Sprague–Dawley rats. Furthermore, to determine studies confirm the suggestion that serotonin and glutamate which serotonergic receptor subtype may mediate this effect, interact in modulating PPI and indicate that the 5-HT2A the 5-HT2A receptor antagonist M100907 (formerly MDL receptor subtype mediates this interaction. -
The Social Brain Meets the Reactive Genome: Neuroscience, Epigenetics and the New Social Biology
HYPOTHESIS AND THEORY ARTICLE published: 21 May 2014 HUMAN NEUROSCIENCE doi: 10.3389/fnhum.2014.00309 The social brain meets the reactive genome: neuroscience, epigenetics and the new social biology Maurizio Meloni* School of Sociology and Social Policy, Institute for Science and Society, University of Nottingham, Nottingham, UK Edited by: The rise of molecular epigenetics over the last few years promises to bring the discourse Jan Slaby, Freie Universität Berlin, about the sociality and susceptibility to environmental influences of the brain to an Germany entirely new level. Epigenetics deals with molecular mechanisms such as gene expression, Reviewed by: Hannah Landecker, University of which may embed in the organism “memories” of social experiences and environmental California Los Angeles, USA exposures. These changes in gene expression may be transmitted across generations Karola Stotz, Macquarie University, without changes in the DNA sequence. Epigenetics is the most advanced example of Australia the new postgenomic and context-dependent view of the gene that is making its way into *Correspondence: contemporary biology. In my article I will use the current emergence of epigenetics and its Maurizio Meloni, School of Sociology and Social link with neuroscience research as an example of the new, and in a way unprecedented, Policy, Institute for Science and sociality of contemporary biology. After a review of the most important developments Society, University of Nottingham, of epigenetic research, and some of its links with neuroscience, in the second part Law and Social Science Building, I reflect on the novel challenges that epigenetics presents for the social sciences for a University Park, Nottingham NG7 2RD, UK re-conceptualization of the link between the biological and the social in a postgenomic age. -
From 1957 to Nowadays: a Brief History of Epigenetics
International Journal of Molecular Sciences Review From 1957 to Nowadays: A Brief History of Epigenetics Paul Peixoto 1,2, Pierre-François Cartron 3,4,5,6,7,8, Aurélien A. Serandour 3,4,6,7,8 and Eric Hervouet 1,2,9,* 1 Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; [email protected] 2 EPIGENEXP Platform, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France 3 CRCINA, INSERM, Université de Nantes, 44000 Nantes, France; [email protected] (P.-F.C.); [email protected] (A.A.S.) 4 Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l’Ouest, 44805 Saint Herblain, France 5 Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), 44000 Nantes, France 6 EpiSAVMEN Network (Région Pays de la Loire), 44000 Nantes, France 7 LabEX IGO, Université de Nantes, 44000 Nantes, France 8 Ecole Centrale Nantes, 44300 Nantes, France 9 DImaCell Platform, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France * Correspondence: [email protected] Received: 9 September 2020; Accepted: 13 October 2020; Published: 14 October 2020 Abstract: Due to the spectacular number of studies focusing on epigenetics in the last few decades, and particularly for the last few years, the availability of a chronology of epigenetics appears essential. Indeed, our review places epigenetic events and the identification of the main epigenetic writers, readers and erasers on a historic scale. This review helps to understand the increasing knowledge in molecular and cellular biology, the development of new biochemical techniques and advances in epigenetics and, more importantly, the roles played by epigenetics in many physiological and pathological situations. -
Epigenetics Analysis and Integrated Analysis of Multiomics Data, Including Epigenetic Data, Using Artificial Intelligence in the Era of Precision Medicine
biomolecules Review Epigenetics Analysis and Integrated Analysis of Multiomics Data, Including Epigenetic Data, Using Artificial Intelligence in the Era of Precision Medicine Ryuji Hamamoto 1,2,*, Masaaki Komatsu 1,2, Ken Takasawa 1,2 , Ken Asada 1,2 and Syuzo Kaneko 1 1 Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; [email protected] (M.K.); [email protected] (K.T.); [email protected] (K.A.); [email protected] (S.K.) 2 Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project, 1-4-1 Nihonbashi, Chuo-ku, Tokyo 103-0027, Japan * Correspondence: [email protected]; Tel.: +81-3-3547-5271 Received: 1 December 2019; Accepted: 27 December 2019; Published: 30 December 2019 Abstract: To clarify the mechanisms of diseases, such as cancer, studies analyzing genetic mutations have been actively conducted for a long time, and a large number of achievements have already been reported. Indeed, genomic medicine is considered the core discipline of precision medicine, and currently, the clinical application of cutting-edge genomic medicine aimed at improving the prevention, diagnosis and treatment of a wide range of diseases is promoted. However, although the Human Genome Project was completed in 2003 and large-scale genetic analyses have since been accomplished worldwide with the development of next-generation sequencing (NGS), explaining the mechanism of disease onset only using genetic variation has been recognized as difficult. Meanwhile, the importance of epigenetics, which describes inheritance by mechanisms other than the genomic DNA sequence, has recently attracted attention, and, in particular, many studies have reported the involvement of epigenetic deregulation in human cancer. -
Behavioral Epigenetics and the Developmental Origins of Child Mental Health Disorders
Journal of Developmental Origins of Health and Disease (2012), 3(6), 395–408. REVIEW & Cambridge University Press and the International Society for Developmental Origins of Health and Disease 2012 doi:10.1017/S2040174412000426 Behavioral epigenetics and the developmental origins of child mental health disorders B. M. Lester1,2,3,4*, C. J. Marsit5, E. Conradt1,4, C. Bromer6 and J. F. Padbury3,4 1Brown Center for the Study of Children at Risk at Women and Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Providence, RI, USA 2Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA 3Department of Pediatrics, Warren Alpen Medical School of Brown University, Providence, RI, USA 4Department of Pediatrics, Women and Infants Hospital of Rhode Island, Providence, RI, USA 5Departments of Pharmacology & Toxicology and Community & Family Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USA 6Department of Neuroscience, Brown University, Providence, RI, USA Advances in understanding the molecular basis of behavior through epigenetic mechanisms could help explain the developmental origins of child mental health disorders. However, the application of epigenetic principles to the study of human behavior is a relatively new endeavor. In this paper we discuss the ‘Developmental Origins of Health and Disease’ including the role of fetal programming. We then review epigenetic principles related to fetal programming and the recent application of epigenetics to behavior. We focus on the neuroendocrine system and develop a simple heuristic stress-related model to illustrate how epigenetic changes in placental genes could predispose the infant to neurobehavioral profiles that interact with postnatal environmental factors potentially leading to mental health disorders. -
The Neurobiology of Trauma Dr
The Neurobiology of Trauma Dr. Casey Hanson Sherman Counseling April 12, 2017 Disclaimer: This presentation includes examples, discussion and video which may be triggering to audience members. We each have our own history and pathways. Please feel free to exit the presentation at any time. The presenter will remain available after the presentation for any concerns or questions Training Objectives Synaptic Activity, Neurotransmitters, Nervous system responses, and Brain Structures associated with stress and trauma. How traumatic events impact an individual’s emotional and behavioral presentations. How the brain processes and recalls traumatic events. The developing brain, adverse childhood experiences, neuroplasticity and resilience. Trauma Alters How the Brain Works Young brains are constantly Most Neuronal Re-aligning neurons- at development such a rate occurs after birth The adult brain could not match Genes provide the Basic blueprint Science of Early Brain and Child Development Brain architecture is constructed by processes that begin before birth and continue into adulthood Skill begets skill as brains are built in a hierarchical fashion – bottom up, increasing complex circuits and skills built on top of simple circuits and skills over time The interaction of genes and experience shapes the circuitry of the developing brain Shonkoff, 2002 The Brain Matters • The human brain is responsible for everything we do. Cry, laugh, walk, talk, create the brain is responsible for all. • The brain - one hundred billion nerve cells in a complex net of continuous activity • The brain’s functioning is a reflection of our experiences. The Developing Brain Without healthy, safe, reciprocal relationships the brain’s architecture does not form as expected, which can lead to disparities in learning and behavior. -
Epigenetics: the Biochemistry of DNA Beyond the Central Dogma
Epigenetics: The Biochemistry of DNA Beyond the Central Dogma Since the Human Genome Project was completed, the newly emerging field of epigenetics is providing a basis for understanding how heritable changes, other than those in the DNA sequence, can influence phenotypic variation. Epigenetics, essentially, affects how genes are read by cells and subsequently how they produce proteins. The interest in epigenetics has led to new findings about the relationship between epigenetic changes and a host of disorders including cancer, immune disorders, and neuropsychiatric disorders. The field of epigenetics is quickly growing and with it the understanding that both the environment and lifestyle choices can directly interact with the genome to influence epigenetic change. This unit is designed to provide a detailed look at the influence of epigenetics on gene expression through developmental stages, tissue-specific needs, and environmental impacts. Students will complete this unit with the understanding that gene regulation and expression is truly “above the genome” and well beyond the simplified mechanism of the Central Dogma of Biology. University of Florida Center for Precollegiate Education and Training www.cpet.ufl.edu 1 EPIGENETICS: THE BIOCHEMISTRY OF DNA www.cpet.ufl.edu 2 Author: Susan Chabot This curriculum was developed as part of Biomedical Explorations: Bench to Bedside, which is supported by the Office Of The Director, National Institutes Of Health of the National Institutes of Health under Award Number R25 OD016551. The content -
Mechanism of Action of Antidepressants and Mood Stabilizers
79 MECHANISM OF ACTION OF ANTIDEPRESSANTS AND MOOD STABILIZERS ROBERT H. LENOX ALAN FRAZER Bipolar disorder (BPD), the province of mood stabilizers, the more recent understanding that antidepressants share has long been considered a recurrent disorder. For more this property in UPD have focused research on long-term than 50 years, lithium, the prototypal mood stabilizer, has events, such as alterations in gene expression and neuroplas- been known to be effective not only in acute mania but ticity, that may play a significant role in stabilizing the clini- also in the prophylaxis of recurrent episodes of mania and cal course of an illness. In our view, behavioral improvement depression. By contrast, the preponderance of past research and stabilization stem from the acute pharmacologic effects in depression has focused on the major depressive episode of antidepressants and mood stabilizers; thus, both the acute and its acute treatment. It is only relatively recently that and longer-term pharmacologic effects of both classes of investigators have begun to address the recurrent nature of drugs are emphasized in this chapter. unipolar disorder (UPD) and the prophylactic use of long- term antidepressant treatment. Thus, it is timely that we address in a single chapter the most promising research rele- vant to the pharmacodynamics of both mood stabilizers and MOOD STABILIZERS antidepressants. As we have outlined in Fig. 79.1, it is possible to charac- The term mood stabilizer within the clinical setting is com- terize both the course and treatment of bipolar and unipolar monly used to refer to a class of drugs that treat BPD. -
Neuropsychopharmacology (2015) 40, 2853–2855 © 2015 American College of Neuropsychopharmacology
Neuropsychopharmacology (2015) 40, 2853–2855 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Commentary Neuropsychopharmacology: Reflections on 40 Volumes Alan Frazer*,1 1 Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA Neuropsychopharmacology (2015) 40, 2853–2855; doi:10.1038/npp.2015.290 This issue completes volume 40 of Neuropsychopharmaco- methodology has not followed in concert with pre-clinical logy (NPP), with the first issue published in December, 1987. advances such that most efficacy studies still lump together This should be distinguished from our 40th anniversary; what are heterogeneous groups of patients. One might say for the first several years, issues were thin, months were how can we subdivide in the absence of biomarkers, which skipped, and multiple volumes were published per year. To do not exist? But one might also ask how can we hope to find commemorate this accomplishment, the editor-in-chief a biomarker among a group of patients that might have 3, 7, (Dr Carlezon) asked me as in-coming ACNP President to or 10 different pathologies, all leading to the same behavioral write a brief overview of my views on the developments in output. Talk about the chicken and the egg! our field over this time period, using highly cited articles Another theme that continues into the present is the time- published in NPP as a guide. dependent, downstream consequences of acute actions of Early on, two articles highlight themes that continue today. some type of psychotherapeutic drugs that correlate better One is the development of animal models for psychiatric with optimal clinical improvement. -
Pharmacogenomics: the Promise of Personalized Medicine for CNS Disorders
Neuropsychopharmacology REVIEWS (2009) 34, 159–172 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $30.00 REVIEW ............................................................................................................................................................... www.neuropsychopharmacology.org 159 Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders Jose de Leon*,1,2,3,4 1 2 Mental Health Research Center, Eastern State Hospital, University of Kentucky, Lexington, KY, USA; College of Medicine, 3 4 University of Kentucky, Lexington, KY, USA; College of Pharmacy, University of Kentucky, Lexington, KY, USA; Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, Medical School, University of Granada, Granada, Spain This review focuses first on the concept of pharmacogenomics and its related concepts (biomarkers and personalized prescription). Next, the first generation of five DNA pharmacogenomic tests used in the clinical practice of psychiatry is briefly reviewed. Then the possible involvement of these pharmacogenomic tests in the exploration of early clinical proof of mechanism is described by using two of the tests and one example from the pharmaceutical industry (iloperidone clinical trials). The initial attempts to use other microarray tests (measuring RNA expression) as peripheral biomarkers for CNS disorders are briefly described. Then the challenge of taking pharmacogenomic tests (compared to drugs) into clinical practice is explained by focusing on regulatory